Menlo Park, California-based Orca Bio closed on a Series D financing worth $192 million, bringing the total raised since 2016 to $300 million.
U.K.-based Bit Bio, a spinout of Cambridge University and previously known as Elpis Biotechnology, secured $41.5 million in a Series A funding round that will be used to support the company’s goal to transition biology into engineering.
While COVID-19 has caused the delay in some clinical trials and hampered workflow in the biopharma industry due to social distancing concerns, some companies have pushed ahead with initial public offerings (IPO) in hopes of securing investor monies to support drug and business development.
Full-service health and wellness agency Fingerpaint is forming Photo 51, a new consultancy focused solely on gene and cell therapies.
One day, cell and gene therapies will be as common as small molecules and antibody-based therapies are today, according to panelists at BIO 2020.
Roche and Innovent Biologics announced a strategic R&D collaboration to discover and develop bispecific antibodies and multiple cell therapies for the treatment of hematological and solid cancers.
Watertown, Massachusetts-based SQZ Biotechnologies closed on a $65 million Series D round, led by Temasek with participation from another new large, U.S.-based fund.
Waltham, Massachusetts-based TScan Therapeutics entered a collaboration agreement with Novartis to discover and develop novel T-cell Receptor (TCR)-engineered T-cell therapies for solid tumors.
MultiStem, a cell therapy in development at Athersys, was recently designated “Highly Relevant” as a Potential Therapy for COVID-19 by BARDA. This is the only therapy in development that targets acute respiratory distress syndrome (ARDS), the pneumonia-like condition that leads to severe illness and death among COVID-19 patients, and is the only one ARDS therapy that has also received Fast Track designation from the FDA.
Business updates for various pharma and life science companies around the globe.